Mavorixafor is a small-molecule CXCR4 antagonist used to enhance the mobilization of hematopoietic stem cells (HSCs) into peripheral blood. It is a targeted pharmaceutical compound that blocks signaling between CXCR4 and its ligand CXCL12, a pathway involved in retaining hematopoietic stem cells within the bone marrow.
Mavorixafor is approved for use in patients with WHIM syndrome, a rare primary immunodeficiency characterized by neutropenia and other abnormalities associated with impaired leukocyte trafficking.
Mavorixafor is a synthetic small-molecule compound with the molecular formula C29H41ClN6O3 and a molecular weight of approximately 557.13 g/mol.
Its CAS Number is 1108744-86-4.
Mavorixafor is supplied as a pharmaceutical-grade active pharmaceutical ingredient for the development and manufacture of pharmaceutical formulations.
Mavorixafor selectively antagonizes the C-X-C chemokine receptor type 4 (CXCR4).
The CXCR4 receptor interacts with CXCL12 and contributes to retention of hematopoietic stem and progenitor cells in the bone marrow. By blocking CXCR4 signaling, mavorixafor reduces CXCR4-mediated retention and promotes the movement of hematopoietic stem cells and mature neutrophils into the peripheral circulation.
This mechanism supports improvement in circulating neutrophil and lymphocyte counts in patients with WHIM syndrome.
Mavorixafor is used for the treatment of WHIM syndrome in adults and pediatric patients aged 12 years and older, according to current U.S. prescribing information.
It is marketed in the United States under the brand name Xolremdi and is administered orally.
Mavorixafor API can be evaluated using validated analytical methods for identification, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
HPLC and other validated chromatographic and spectroscopic methods may be used for identity, assay and purity testing. Appropriate controls should be established for process-related impurities, degradation products and residual solvents.
Final acceptance criteria should be based on the applicable manufacturer's approved drug-substance specification and Certificate of Analysis.
Mavorixafor should be stored in a tightly closed pharmaceutical-grade container under controlled conditions and protected from excessive heat, moisture and direct light.
Specific storage and transportation requirements should follow the applicable manufacturer's approved specification.
Mavorixafor API may be supplied for qualified pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Mavorixafor API is available for qualified pharmaceutical development and manufacturing requirements. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |
| Melting Point | Approximately 130–135 °C |